Oncotarget

Research Papers:

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients

Isabel Stückrath, Brigitte Rack, Wolfgang Janni, Bernadette Jäger, Klaus Pantel and Heidi Schwarzenbach _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:13387-13401. https://doi.org/10.18632/oncotarget.3874

Metrics: PDF 1433 views  |   HTML 1602 views  |   ?  


Abstract

Isabel Stückrath1, Brigitte Rack2, Wolfgang Janni3, Bernadette Jäger3, Klaus Pantel1 and Heidi Schwarzenbach1

1 Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany

2 First Department of Obstetrics and Gynecology, Ludwig Maximilians University of Munich, Germany

3 Department of Gynecology and Obstetrics, University Hospital Ulm, Germany

Correspondence to:

Heidi Schwarzenbach, email:

Keywords: cell-free miRs, chemotherapy, invasion, proliferation, tumor progression

Received: December 22, 2014 Accepted: April 03, 2015 Published: April 19, 2015

Abstract

Within the multicenter SUCCESS trial, we investigated the association of plasma microRNAs with different subtypes of invasive breast cancer.

Six miRs (miR-16, miR-27a, miR-107, miR-130a, miR-132 and miR-146a) were selected from microarray profiling and further validated in plasma of 111 breast cancer patients before and after chemotherapy and 46 healthy women by quantitative real-time PCR.

Plasma levels of miR-16 (p = 0.0001), miR-27a (p = 0.039) and miR-132 (p = 0.020) were higher in breast cancer patients before chemotherapy than healthy women. With the exception of miR-16, the increased levels of miR-27a (p = 0.035) and miR-132 (p = 0.025) decreased after chemotherapy to those observed in healthy women. Levels of miR-16 (p = 0.019), miR-107 (p = 0.036), miR-130a (p = 0.027) and miR-146a (p = 0.047) were different between lymph node -positive and -negative patients, while the levels of miR-130a (p = 0.001) and miR-146a (p = 0.025) also differed between HER2-positive and -negative status. Estrogen-receptor negative tumors displayed higher concentrations of circulating miR-107 than their counterparts (p = 0.035). However, overexpression of miR-107 in MCF-7 cells did not downregulate estrogen receptor protein. Altered expression levels of miR-107 influenced the migration and invasion behavior of MCF-7 and MDA-MB-231 cells.

Our data indicate differential concentrations of plasma miR-16, miR-107, miR-130a and miR-146a in different breast cancer subtypes, suggesting a potential role of these miRs in breast cancer biology and tumor progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3874